24 results about "Endothelial proliferation" patented technology

The invention belongs to the technical field of biological medicine, and discloses a high-efficiency vascular endothelial cell targeting vesicle system, which is prepared from hemangioma stem cell derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs, and is characterized in that the endothelial cell targeting vesicle system is prepared from the hemangioma stem cell derived exosome HemSCs-Exos and the bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs; meanwhile, the invention further discloses a preparation method of the vesicle system and application of the vesicle system in promoting proliferation and migration of endothelial cells. Different from existing targeting modification, the ingenious targeting relationship between the BMSCs-ABs and the endothelial cells belongs to non-special modification combination, and is simple and efficient; the fusion between the double EVs has the characteristic of realizing '1 + 1gt, 2', not only retains the treatment components of the HemSCs-Exos and the BMSCs-ABs, but also the fused eHEs has remarkable cell specificity distribution, and the fusion mode is simple and stable.

The invention provides a composition containing SVF and hyaluronic acid and application of the composition to tissue repair. Furthermore, the invention obtains the angiogenesis peptide for promoting angiogenesis through screening and identification, and the polypeptide has better effects of promoting endothelial cell proliferation and angiogenesis. The composition prepared by mixing the angiogenesis peptide MA-R-5 capable of promoting angiogenesis with SVF and fat particles and adding hyaluronic acid has the advantages of better reducing the degradation of a graft and promoting the generation of new vessels around the graft, and has a wide application prospect.

This invention belongs to the field of biomedical technology, specifically relating to a madder-derived exosome-like nanovesicle, an artificial blood vessel, and their preparation and application. This invention utilizes differential centrifugation and sucrose density gradient centrifugation techniques to extract high-purity, highly active exosome-like nanovesicles from madder. Then, polydopamine is loaded onto the surface of a small-diameter polyurethane artificial blood vessel, which is then immersed in a suspension of madder-derived exosome-like nanovesicles to obtain a small-diameter artificial blood vessel loaded with madder-derived exosome-like nanovesicles. These madder-derived exosome-like nanovesicles can effectively promote endothelial cell proliferation and inhibit reactive oxygen species generation; animal experiments show unobstructed blood flow under ultrasound. The small-diameter artificial blood vessel loaded with madder-derived exosome-like nanovesicles can simultaneously achieve in vivo endothelialization and vascular patency, possessing significant clinical application value.

The invention relates to the technical field of biomedical materials. The invention discloses a Schiff base-sulfonated hyaluronic acid light-cured microsphere as well as a preparation method and application thereof. The microspheres are prepared by condensing DL-lysine and paeonol to generate Schiff base, then conjugating the Schiff base with sulfonated hyaluronic acid through a carbodiimide chemical method, and finally molding by adopting a microfluidic technology and carrying out ultraviolet curing. The metal chelation characteristic of Schiff base is combined with the precise structure regulation advantage of the microspheres, and the prepared microspheres show an excellent synergistic effect when applied to the surfaces of implant materials such as degradable magnesium alloy, iron alloy and zinc alloy: the corrosion resistance of a base material can be remarkably improved, an effective protective layer is formed, and the service life of the microspheres is prolonged. Meanwhile, the compound has multiple biological functions of promoting endothelial cell proliferation, inhibiting excessive proliferation of smooth muscle cells and regulating and controlling macrophages to be polarized to anti-inflammatory phenotypes, and has a wide application prospect in the biomedical fields of intravascular stents, bone fixing instruments and the like.

The invention relates to hypoxia response therapeutic VEGFA (vascular endothelial growth factor A) mRNA (messenger Ribonucleic Acid) and application thereof. The mRNA comprises a 5'end cap, a 5 'UTR (Untranslated Region) containing a Kozak sequence, VEGFA ORF (Open Region Fragment), a 3' UTR containing an RNA (Ribonucleic Acid) binding protein HuR binding site, a RhoBAST fluorescent aptamer at the tail end of the 3 'UTR and a PolyA tail. According to the design, through a HuR hypoxia-dependent nuclear plasma transport mechanism, the stability of mRNA in hypoxic cells is improved by 2.5 times, the protein expression quantity is improved by 2 times, and proliferation of endothelial cells is remarkably promoted. Further disclosed is a VEGFA mRNA delivery system based on engineered extracellular vesicles (EVs): EVs surface modified kidney targeting peptide LTH. The system is efficiently accumulated in ischemic kidneys, VEGFA expression is remarkably enhanced, and abnormal vascular hyperplasia of external renal organs is avoided. Animal experiments prove that the survival rate of a renal ischemia-reperfusion injury model can be increased to 100% by intravenous injection of drug-loaded EVs, and the capillary density is remarkably increased 7 days after treatment. The invention is suitable for treating ischemic diseases, organ ischemia reperfusion injury or chronic wounds and the like, and has the advantages of accurate targeting, hypoxia response, high stability and safety.

The invention provides a protein. The protein comprises an amino acid sequence as shown in SEQ ID NO: 3, 4 or 6. In some embodiments, the protein is a FHTFF 1.5 forbidden factor. The protein disclosed by the invention can inhibit angiogenesis by inhibiting proliferation and migration of vascular endothelial cells, and the recombinant protein can also resist telangiectasis below the skin and can also resist blood supply of tumor cells. The invention also provides coding nucleic acid of the protein, a carrier, a cell containing the protein and application of the protein as an innovative biological material in the large health fields of medical instruments, biological medicines, facial beautification, aging resistance and the like.

The invention belongs to the field of biological medicine, and particularly relates to an application of rose natural extracellular vesicles in preparation of cardiovascular protection products, the rose extracellular vesicles are extracted through a classical ultracentrifugation method, biological characteristics of the rose extracellular vesicles are identified and confirmed through a transmission electron microscope (a tea tray type nano vesicle structure) and a nano-particle tracking analyzer (80-150 nm, 1.8 E + 11 Particle / mL) in a combined mode, and the application of the rose extracellular vesicles in preparation of cardiovascular protection products is achieved. After research, it is found that when the rose extracellular vesicles are applied to cardiovascular products, the rose extracellular vesicles have the effects of (a) promoting endothelial cell proliferation; (b) inhibiting endothelial cell apoptosis; and (c) a function of enhancing oxidation resistance. The invention verifies the application of the rose natural extracellular vesicles, and the experimental research finds that the rose extracellular vesicles as a natural active ingredient have a remarkable effect in synchronous triple regulation (proliferation promotion-apoptosis resistance-oxidation resistance) of human umbilical vein endothelial cells (HUVEC), and can be used for preparing the rose natural extracellular vesicles. And a new way is provided for developing non-engineering cardiovascular protection products with high safety performance.

The invention discloses an anticoagulant polymer-ZIF nano drug delivery system composite material and application, and particularly relates to the technical field of coating materials, the composite material is prepared by fixing an anticoagulant polymer and a ZIF nano drug delivery system through coordination; the anticoagulant polymer is at least one of hydroheparin, thiolated polyethylene glycol, a methacrylic acid phosphorylcholine-based polymer, a methacrylic acid sulphobetaine-based polymer and a methacrylic acid carboxyl betaine-based polymer; and the ZIF nano drug loading system is a ZIF nano carrier modified by a drug. According to the composite material, an organic-inorganic hybrid ZIF loaded medicine which is low in cost and stable in performance is utilized to construct a nano medicine carrying system, so that after the surface of an implanted instrument is coated with the composite material, endothelial cell proliferation can be promoted, active oxygen can be removed, and then the endothelial function is accelerated to be repaired.

This invention provides a protein comprising the amino acid sequence shown in SEQ ID NO: 3, 4, or 6. In some embodiments, the protein is FHTFF1.5 activator. The protein of this invention may inhibit angiogenesis by inhibiting the proliferation and migration of vascular endothelial cells; the recombinant protein may also combat telangiectasia under the skin and inhibit blood supply to tumor cells. This invention also provides the encoding nucleic acid of the protein, a vector, cells containing the protein, and its uses as innovative biomaterials in the fields of medical devices, biomedicine, and anti-aging.

The invention belongs to the technical field of biomedical composite materials, and discloses a copper-based MOF modified small-caliber polyurethane artificial blood vessel and a preparation method. The copper-based metal organic framework is used as a functional carrier to be compounded with polyurethane, the artificial blood vessel with the inner diameter smaller than or equal to 6 mm is prepared through the electrostatic spinning technology, and synergistic release of copper ions, nitric oxide and medicine molecules is achieved; the preparation process comprises the steps of synthesis of the copper-based metal organic framework, preparation of a polyurethane solution, drug loading, electrostatic spinning forming and the like. According to the invention, a mechanical adaptation-biological regulation synergistic system is innovatively constructed, so that proliferation of endothelial cells is effectively promoted, excessive proliferation of smooth muscle cells is inhibited, and an ideal microenvironment is provided for vascular repair; the clinical problems of mechanical property mismatch, thrombosis, intimal hyperplasia and the like of the small-caliber artificial blood vessel are solved, and the preparation method is stable in process and low in cost and has important clinical application value.

The application belongs to the technical field of medicine, and particularly relates to application of a beta-lactam compound in preparation of anti-inflammatory drugs. The application is found through research and verified through experiments that the beta-lactam compound is combined with the surface of alpha and beta tubulin proteins, inhibits tubulin aggregation, and thus inhibits various cell processes in which microtubules participate; the beta-lactam compound inhibits inflammatory reactions through the following pathways: inhibiting immune activation, NLRP3 inflammasome activation and Caspase-1 activation; inhibiting neutrophil recruitment, adhesion and chemokine release; inhibiting vascular endothelial growth factor secretion and endothelial cell proliferation, and thus can be used for preparing anti-inflammatory drugs, including for treating local inflammatory reaction diseases such as acute gout, familial Mediterranean fever, chronic kidney disease, pancreatitis, sarcopenia and the like caused by inflammation, and inflammation-related cardiovascular diseases such as ischemia-reperfusion injury, diabetes, atherosclerosis, pericarditis, acute coronary syndrome and the like.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

The application belongs to the technical field of biological medicine, and discloses a kind of high-efficiency vascular endothelial cell targeting vesicle system, which is prepared by hemangioma stem cell-derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell-derived apoptotic body BMSCs-ABs, and the application further discloses a preparation method of the vesicle system and its application in promoting endothelial cell proliferation and migration. Unlike existing targeted modification, the ingenious targeting relationship between BMSCs-ABs and endothelial cells in the application belongs to the combination of non-special modification, which is simple and efficient. The fusion between double EVs has the characteristics of "1+1>2", which not only retains the therapeutic components of HemSCs-Exos and BMSCs-ABs, but also has a significant cell-specific distribution after fusion. The fusion method is simple and stable.

The application relates to the field of occluders, in particular to a double-layer left atrial appendage occluder, which comprises a conveying pipe, a pushing structure and an occlusion structure, the conveying pipe is internally provided with a pushing steel cable, the left end of the pushing steel cable is provided with a pushing head, the upper end of the conveying pipe is provided with a liquid injection pipe, the right end of the conveying pipe is connected with the pushing structure for sending the occluder, and the pushing structure is internally placed with the occlusion structure. The specification of the occluder is selected, the sheath tube mark position is flush with the left atrial appendage opening, whether the conveying steel cable is connected with the conveyor is checked, the barb is safe, stable, easy to recycle, not easy to fall off in the implantation process; the barb can be recycled and unfolded repeatedly, the barb does not deform, the hook-shaped distal end reduces the risk of damaging the atrial wall, the opening design makes the occlusion more stable, the porosity and thickness are moderate, the thrombus overflow is effectively prevented, the weaving mode is beneficial to endothelial cell proliferation, the endothelialization process is accelerated, and the use effect of the occluder is improved.

The invention discloses a gel dressing capable of repairing skin for a long time and a preparation method of the gel dressing. The gel dressing is prepared from 6-10 parts of self-crosslinking sodium hyaluronate, 5-6 parts of sodium chloride, 4-5 parts of cysteine hydrochloride, 3-4 parts of plant defensin polypeptide, 1-3 parts of flammulina velutipes polysaccharide and 10-30 parts of pure water as the balance. The preparation method of the gel dressing comprises the following preparation steps: S1, dissolving crushed cysteine hydrochloride and sodium chloride in pure water, and stirring and dissolving at 80 DEG C to obtain a dissolved solution for later use; s2, plant defensin polypeptide and flammulina velutipes polysaccharide are added into the dissolved solution, and a mixed solution is obtained after sterilization treatment; the self-crosslinking sodium hyaluronate has a polymer fiber network structure, can play a physical barrier role when being coated on the tissue surface, and can prevent adhesion, inhibit release of local inflammatory media, resist local fibrosis, inhibit proliferation of granulation tissues and endothelial cells, regulate new collagen arrangement and promote scar-free healing of wounds.

The invention discloses conductive hydrogel based on bioactive polypeptide as well as a preparation method and application of the conductive hydrogel, and belongs to the technical field of biological medicines. The invention discloses conductive hydrogel based on bioactive polypeptide. The conductive hydrogel is beneficial to stable transmission of an electric signal, regulation of the level of active oxygen in a body and synchronous contraction of myocardial cells. And a stable platform is provided for continuous release of the angiogenic peptide. In-vitro research shows that the compound has excellent cell compatibility, can remarkably promote endothelial cell proliferation, and has efficient active oxygen scavenging capacity. In a rat myocardial infarction model, the heart function of a mouse is remarkably improved by the composite hydrogel. Histological and immunohistochemical tests further prove the therapeutic effect of the traditional Chinese medicine composition. Therefore, the prepared composite hydrogel can adjust the myocardial microenvironment and electrical activity at the same time, so that the recovery process of myocardial infarction is accelerated, and the composite hydrogel has wide application potential in the aspect of treating myocardial infarction.

A biliary tract stent for inhibiting scar and endothelial proliferation comprises a left segment and a right segment, characterized in that: an intermediate segment is arranged between the left segment and the right segment, the left segment, the right segment and the intermediate segment are all mesh structures, the intermediate segment is a retracted type, so that the overall structure of the biliary tract stent is slightly smaller in the middle and larger at both ends; the intermediate segment is provided with a treatment layer, which is used to inhibit scar and endothelial proliferation; the technical scheme of the application adopts the synergistic effect of radiotherapy and mechanical support to accurately inhibit fibroblast proliferation at the stenosis site of the biliary tract anastomotic mouth, inhibit scar and reduce endothelial proliferation, solves the problem of repeated restenosis after traditional stent implantation, and greatly prolongs the patency time of the stent.

The present invention relates to the field of biomedicine technology, and in particular to a culture medium, culture method and application for endothelial progenitor cells. The present invention improves the culture medium for endothelial progenitor cells, and the endothelial progenitor cells prepared therefrom have higher proliferation activity and better angiogenesis ability, and their ability to promote the secretion of active factors is the strongest. Factors such as IL-10 and TGF-β secreted by EPCs have the potential to inhibit mast cell degranulation, reduce the release of histamine and inflammatory mediators, and thus relieve wheals and itching. In addition, EPCs promote endothelial cell proliferation by secreting factors such as VEGF and Ang-1, repair damaged vascular endothelium, and reduce vascular leakage and edema. In urticarial vasculitis, EPCs can inhibit excessive proliferation of the vascular endothelium and relieve chronic inflammation. The culture medium of the present invention can be used for endothelial progenitor cell culture, which is helpful for screening potential drugs for treating urticaria and has great application value.

The invention provides application of an FGF5 gene inhibitor in preparation of anti-tumor angiogenesis drugs, and belongs to the technical field of biological medicines. The invention provides application of a reagent for inhibiting expression of an FGF5 coding gene or a reagent for inhibiting expression or functions of FGF5 in preparation of anti-tumor angiogenesis drugs. In the invention, tumor angiogenesis can be inhibited by inhibiting expression of FGF5. Results of the embodiment of the invention show that overexpression of the FGF5 protein and the coding gene thereof can effectively promote migration and invasion of human umbilical veins and tubule formation, and knock-down of expression of the FGF5 inhibits migration and invasion ability of the human umbilical veins and tubule formation ability. A subcutaneous tumor generation experiment further verifies that the FGF5 can promote the growth of a subcutaneous tumor HGC27 of a nude mouse, and promote tumor angiogenesis and tumor endothelial cell proliferation and migration.

The invention belongs to the technical field of medicine preparation, and particularly relates to application of hypoglycosylated apolipoprotein D in preparation of a medicine for repairing a blood brain barrier. Experiments in the invention show that in the molecular level, the binding affinity of low glycosylated apolipoprotein D (ApoD) and CD36 is increased by about 9 times compared with that of high glycosylated apolipoprotein D, and a key mechanism foundation is laid for function exertion; in an MCAO (middle cerebral artery occlusion) stroke model (middle cerebral artery occlusion model), the hypoglycosylated apolipoprotein D can remarkably repair a capillary structure, reduce an infarct area, improve neurological dysfunction, reduce blood-brain barrier permeability and enhance capillary perfusion, and the treatment efficiency is far superior to that of the hyperglycosylated apolipoprotein D; aiming at an elderly stroke model, the hypoglycosylated ApoD can improve the survival rate of mice, repair disordered and expanded capillaries, inhibit pathological endothelial cell proliferation and strengthen the integrity of a blood-brain barrier, and the hypoglycosylated ApoD can still continuously improve neurological functions and vascular phenotypes 30 days after stroke.

The invention discloses a modified bacterial cellulose hydrogel membrane and a preparation method and application thereof, and belongs to the technical field of antibacterial cellulose membranes.The preparation method comprises the steps that Cu-coated ZIF with high reactive oxygen generation is prepared firstly, so that wound-related pathogens are killed, then collagen deposition encapsulation is conducted on the Cu-coated ZIF through fish collagen peptide, Col-Cu-coated ZIF is obtained, and the modified bacterial cellulose hydrogel membrane is obtained. Tissue regeneration of chronic wounds is enhanced, and cell migration and angiogenesis are promoted. And compounding bacterial cellulose serving as an extracellular matrix with the Col-Cu-coated ZIF to obtain a modified bacterial cellulose hydrogel membrane, namely the Col-Cu-coated ZIF-BC hydrogel membrane. The hydrogel film obtained by adopting the BC base modified by the organic framework material MOF is beneficial to providing an extracellular moist microenvironment, killing pathogenic bacteria, preventing foreign matters from invading wound parts, and accelerating wound healing by promoting angiogenesis and stimulating endothelial cell proliferation and migration.

The present invention relates to an antibody fragment specifically binding to vascular endothelial growth factor (VEGF) and, more specifically, to a dimeric antibody fragment comprising a structure in which two antibody fragments are dimerized by a SARAH domain, and expressing high binding affinity and excellent biological activity for VEGF. The antibody of the present invention inhibits VEGF-induced proliferation of human vascular endothelial cells (HUVEC) and blocks VEGFR2-mediated signaling, and thus effectively inhibits angiogenesis.

The invention belongs to the technical field of biomedical materials, and discloses a decellularized cornua cervi pantotrichum (dECM)-based multifunctional composite hydrogel for promoting healing of diabetic wounds and a preparation method thereof.The preparation method comprises the steps that decellularization treatment and amination modification are conducted on cornua cervi pantotrichum, and then the cornua cervi pantotrichum is dissolved in PBS to obtain a mixed solution A; meanwhile, dextran is dissolved in PBS after being subjected to formylation modification, and a mixed solution B is obtained; carrying out hydrothermal synthesis on magnesium chloride (MgCl2) and epigallocatechin gallate (EGCG) to obtain Mg-EGCG, and adding the mixed solution A into the Mg-EGCG to obtain a mixed solution C; and mixing the mixed solution B and the mixed solution C according to a ratio to obtain the composite hydrogel (Mg-EGCG (at) dECMH). According to the invention, pilose antler dECM and oxidized dextran (ODEX) are creatively selected to form a self-healing hydrogel through a Schiff base reaction, and Mg-EGCG is embedded into a polymeric network to prepare the composite hydrogel. According to the invention, proliferation, migration and vascularization of endothelial cells can be promoted, the oxidative stress level of a wound surface can be effectively reduced, and a suitable microenvironment is provided for healing of a diabetic skin wound.

The present application relates to the technical field of medicine, in particular to the use of a substance specifically binding to KLK8 in the preparation of a product for the prevention, treatment or diagnosis of sepsis, which treats sepsis by: 1) reducing endothelial cell permeability or improving capillary leakage; 2) stimulating the VE-cadherin / Akt / FOXM1 signaling pathway; preferably, selected from up-regulating the expression level of FOXM1 and its downstream target genes, up-regulating the protein level of AKT or p-AKT, or up-regulating the protein level of VE-cadherin; 3) increasing the proliferation rate of endothelial cells; 4) reducing the mortality rate of endothelial cells; 5) increasing the activity of endothelial cells. The present application provides a new treatment strategy for sepsis complicated with microvascular barrier dysfunction.